Skip to main content
BMEA logo

BMEA · Biomea Fusion, Inc. · Metrics

Track BMEA — free
$0.60 +0.02 (+2.58%) At close · Oct 23
Market Cap
$43.50M
Shares
72.48M
Volume · Oct 23 958.01K Avg daily vol (3M) 2.05M

BMEA metrics

61 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.60
Market cap
$43.50M

Price action

20 metrics
Price change (1W)
-30.9%
Price change (30D)
-59.7%
Price change (3M)
-52.0%
Price change (6M)
-68.2%
Price change (YTD)
-51.6%
Price change (1Y)
-56.5%
Trailing year
Price change (5Y)
-94.5%
52-week high
$2.21
52-week low
$0.59
Change from 52-week high
-72.8%
Change from 52-week low
+2.6%
Annualized volatility
91.6%
Annualized volatility (3M)
106.7%
Beta
1.5
RSI (14D)
22.6
Price vs SMA 50
-58.0%
Price vs SMA 200
-56.9%
Avg volume (3M)
2.05M
Relative volume
0.5
Average dollar volume
$2.83M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
72.48M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.6
reciprocal yield 27.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-74.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$58.06M
Net income (TTM)
−$32.54M
Trailing 12 months
Diluted EPS (TTM)
$-0.16
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$-2.20
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.41

Growth

11 metrics
Revenue growth YoY
+0.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+78.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-268.1%
Return on assets
-88.2%
Debt / equity
—
Current ratio
3.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$34.82M
Latest balance sheet
Cash & equivalents
$34.82M
Total assets
$36.87M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$47.19M
Capital expenditures (TTM)
$82,000
R&D (TTM)
$40.78M
SG&A (TTM)
—
Stock compensation (TTM)
$6.95M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
62
13F filer change QoQ
-3
Institutional ownership
36.1%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
12.2%
Private-fund adviser ownership
10.5%
Active holders' share change QoQ
+2.1%
Holder tenure
13.7
Price vs estimated holder cost
-82.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.0%

Short interest

3 metrics
Short interest
19.4%
Latest settlement · 5.7 days to cover
Days to cover
5.7d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1840439 CUSIP 09077A106 13F (30d) 6 filings 6 filers Visit website Investor relations